Plain-English translation of NCT07795814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called EDG-15400 to see if it is safe and tolerable for people with heart failure with preserved ejection fraction — a condition where your heart doesn't pump blood out as weakly as other types of heart failure, but still causes symptoms. Researchers want to understand how well different doses of this medication work and whether it helps people feel better.
Heart failure with preserved ejection fraction is a common type of heart failure that doesn't have many treatment options yet. This trial aims to find out if this new treatment could be a helpful option for people dealing with this condition.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the medication at one of two doses or a placebo (a non-active pill). The study is double-blind, meaning neither you nor the researchers will know which treatment you received. You would visit the clinic multiple times so researchers can check your heart health, take blood tests, and monitor how you are responding to the treatment.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States